Skip to main content

Advertisement

SpringerLink
Log in

Angiogenesis and prostate cancer: Important laboratory and clinical findings

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Prostate cancer is the leading cause of cancer diagnosis in men and the second leading cause of cancer-related death. Androgen ablation is effective initially, and progression of disease often occurs in many patients. Although recent reports have noted a survival benefit when patients with androgen-independent prostate cancer are treated with docetaxel, patients still have disease progression. Angiogenesis plays a pivotal role for the growth, invasion, and metastasis of prostate cancer. Therefore, antiangiogenesis is a promising new therapeutic modality. More than 20 antiangiogenic agents are now in various stages of clinical trials. We discuss current knowledge on controlling tumor angiogenesis and advances in the development of antiangiogenic agents with promising antitumor activity in prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  2. Rini B, Small EJ: An update on prostate cancer. Curr Opin Oncol 2001, 13:204–211.

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J: Tumour angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  4. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757–1763.

    Article  PubMed  CAS  Google Scholar 

  5. Nicholson B, Theodorescu D: Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004, 91:125–150.

    Article  PubMed  CAS  Google Scholar 

  6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4–6.

    Article  PubMed  CAS  Google Scholar 

  7. Cox M, Liu Y, Figg WD: Antiangiogenesis in prostate cancer. Cancer Ther 2004, 2:121–129.

    Google Scholar 

  8. Choy M, Rafii S: Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 2001, 19:181–191.

    Article  PubMed  CAS  Google Scholar 

  9. Sokoloff M, Chung L: Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev 1999, 17:307–315.

    Article  CAS  Google Scholar 

  10. Weidner N, Carroll PR, Flax J, et al.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143:401–409.

    PubMed  CAS  Google Scholar 

  11. McNamara DA, Harmey JH, Walsh TN, et al.: Significance of angiogenesis in cancer therapy. Br J Surg 1998, 85:1044–1055.

    Article  PubMed  CAS  Google Scholar 

  12. Streck C, Zhang Y, Zhou J, et al.: Endostatin-mediated concomitant resistance in neuroblastoma. J Pediatr Surg 2004, 39:405–411.

    Article  PubMed  Google Scholar 

  13. D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082–4085.

    Article  PubMed  CAS  Google Scholar 

  14. Bauer K, Dixon S, Figg W: Inhibition of angiogenesis by thalidomide requires metabolic activation which is speciesdependent. Biochem Pharmacol 1998, 55:1827–1834.

    Article  PubMed  CAS  Google Scholar 

  15. Figg WD, Dahut W, Duray P, et al.: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888–1893.

    PubMed  CAS  Google Scholar 

  16. Drake MJ, Robson W, Mehta P, et al.: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003, 88:822–827.

    Article  PubMed  CAS  Google Scholar 

  17. Dahut WL, Gulley JL, Arlen PM, et al.: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2532–2539. A recent report showing improved response in patients given chemotherapy and an antiangiogenic agent. This report shows that there is promise in the combination agent studies.

    Article  PubMed  CAS  Google Scholar 

  18. Arlen PM, Figg WD, Gulley J, et al.: National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer 2002, 1:153–162.

    PubMed  CAS  Google Scholar 

  19. Braun AG, Harding FA, Weinreb SL: Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986, 82:175–179.

    Article  PubMed  CAS  Google Scholar 

  20. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is speciesdependent. Biochem Pharmacol 1998, 55:1827–1834.

    Article  PubMed  CAS  Google Scholar 

  21. Ando Y, Fuse E, Figg WD: Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002, 8:1964–1973.

    PubMed  CAS  Google Scholar 

  22. Ando Y, Price DK, Dahut WL, et al.: Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 2002, 1:669–673. An important paper aiding in the prediction of response to thalidomide in certain patients.

    PubMed  CAS  Google Scholar 

  23. Wakeling AE, Guy SP, Woodburn JR, et al.: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749–5754.

    PubMed  CAS  Google Scholar 

  24. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003, 284:122–130.

    Article  PubMed  CAS  Google Scholar 

  25. Cohen MH, Williams GA, Sridhara R, et al.: United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10:1212–1218.

    Article  PubMed  CAS  Google Scholar 

  26. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139.

    Article  PubMed  CAS  Google Scholar 

  27. Sgambato A, Camerini A, Faraglia B, et al.: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004, 201:97–105.

    Article  PubMed  CAS  Google Scholar 

  28. Ng SS, Gutschow M, Weiss M, et al.: Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 2003, 63:3189–3194.

    PubMed  CAS  Google Scholar 

  29. Ng SS, MacPherson GR, Gutschow M, et al.: Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 2004, 10:4192–4197. A good paper assessing antitumor effects of thalidomide analogues and predicting the future agents for clinical trials.

    Article  PubMed  CAS  Google Scholar 

  30. Gustavsson H, Welen K, Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005, 62:364–373.

    Article  PubMed  Google Scholar 

  31. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  32. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427–434.

    Article  PubMed  CAS  Google Scholar 

  33. Reese D, Frohlich M, Bok R, et al.: A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC) [abstract]. Proc ASCO 1999, 18:1355.

    Google Scholar 

  34. Picus J: Docetaxel/bevacizumab (Avastin) in prostate cancer. From Chemotherapy Foundation Symposium XXI [abstract]. Cancer Invest 2003, 22:46.

    Google Scholar 

  35. Butler R, Mitchell SH, Tindall DJ, Young CY: Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 2000, 11:49–61.

    PubMed  CAS  Google Scholar 

  36. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000, 405:421–424.

    Article  PubMed  CAS  Google Scholar 

  37. Mueller E, Smith M, Sarraf P, et al.: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000, 97:10990–10995.

    Article  PubMed  CAS  Google Scholar 

  38. Kubota T, Koshizuka K, Williamson EA, et al.: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998, 58:3344–3352.

    PubMed  CAS  Google Scholar 

  39. Smith MR, Manola J, Kaufman DS, et al.: Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004, 101:1569–1574. An interesting clinical study involving the dissemination of knowledge into a clinical application. Although this is a negative study, the ideas and information presented will pave the way for future studies.

    Article  PubMed  CAS  Google Scholar 

  40. D’Amico AV, Moul J, Carroll PR, et al.: Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004, 172:S42-S46.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, 10 Center Drive, Building 10, Room 5A-01, 20892, Bethesda, MD, USA

    Michael C. Cox PharmD, Matthew Permenter BS & William D. Figg PharmD

Authors
  1. Michael C. Cox PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Permenter BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William D. Figg PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cox, M.C., Permenter, M. & Figg, W.D. Angiogenesis and prostate cancer: Important laboratory and clinical findings. Curr Oncol Rep 7, 215–219 (2005). https://doi.org/10.1007/s11912-005-0076-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0076-z

Keywords

Search

Navigation